{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T07:30:08Z","timestamp":1786433408873,"version":"build-2736575974"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Obesity is linked with worse outcomes in hypertrophic cardiomyopathy (HCM). While both bariatric surgery (BS) and GLP-1 receptor agonists (GLP-1RA) promote weight loss and may improve cardiometabolic risk, their comparative outcomes in HCM remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Adults with HCM and body mass index (BMI) \u2265 30 kg\/m were divided into two cohorts: (i) GLP-1 RA users who never had BS, and (ii) BS patients who never received GLP-1 RA. Propensity score matching (1:1) was performed to balance demographics, comorbidities, and medications. Outcomes over 24 months include all-cause mortality, acute heart failure (HF) hospitalization, arrhythmias, change in BMI, and cardiovascular symptoms. Hazard ratios with 95% confidence intervals were estimated using Cox models. Of 5002 patients, 955 were included in each matched cohort after matching (mean age 54 \u00b1 13 years, 70% female, BMI 40.0 kg\/m). GLP-1 RA was associated with a significantly lower observed rate of all-cause mortality compared with BS (2.0% vs. 4.4%; HR 0.46; 95% CI 0.27\u20130.80; P = 0.004) and HF hospitalization (8.7% vs. 14.0%; HR 0.60; 95% CI 0.46\u20130.79; P &amp;lt; 0.001). Similarly, GLP-1 RA use was associated with a lower incidence of composite cardiovascular outcomes (10.7% vs. 17.2%; HR 0.60; 95% CI 0.47\u20130.77; P &amp;lt; 0.001). Rates of arrhythmia and cardiovascular symptoms were comparable between the two groups. BMI reduction was greater after bariatric surgery (\u22124.0 vs. \u22122.6 kg\/m; P &amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In obese patients with HCM, GLP-1 RA therapy was associated with lower all-cause mortality and fewer HF events compared with BS. Future studies are warranted to confirm our findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjqcco\/qcag051","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:48:49Z","timestamp":1774529329000},"page":"731-739","source":"Crossref","is-referenced-by-count":2,"title":["Association of GLP-1 receptor agonists versus bariatric surgery with outcomes in obese patients with hypertrophic cardiomyopathy: a multicenter propensity-matched analysis"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9729-9961","authenticated-orcid":false,"given":"Ahmed K","family":"Mahmoud","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Phoenix, AZ 85054 ,","place":["USA"]},{"name":"Department of Cardiovascular Medicine, Boston Medical Center-Brighton , Boston, MA 02135 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6707-1629","authenticated-orcid":false,"given":"Kamal","family":"Awad","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Phoenix, AZ 85054 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Sheashaa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Phoenix, AZ 85054 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omneya","family":"Kandil","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, Mayo Clinic , Phoenix, AZ 85054 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M","family":"Farina","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Phoenix, AZ 85054 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzi","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Phoenix, AZ 85054 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Abdelnabi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Phoenix, AZ 85054 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7687-9344","authenticated-orcid":false,"given":"Mohamed","family":"Allam","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Phoenix, AZ 85054 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Mital","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Phoenix, AZ 85054 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0052-036X","authenticated-orcid":false,"given":"Justin","family":"Shipman","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Phoenix, AZ 85054 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8750-7880","authenticated-orcid":false,"given":"Said","family":"Alsidawi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Phoenix, AZ 85054 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J","family":"Lester","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Phoenix, AZ 85054 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve R","family":"Ommen","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B","family":"Geske","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Rochester, MN 55905 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Patten","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Boston Medical Center-Brighton , Boston, MA 02135 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7118-2302","authenticated-orcid":false,"given":"Chadi","family":"Ayoub","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Phoenix, AZ 85054 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Arsanjani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic , Phoenix, AZ 85054 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"2026081102581837600_qcag051-B1","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"key":"2026081102581837600_qcag051-B2","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"2026081102581837600_qcag051-B3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jamacardio.2019.4268","article-title":"Association of obesity with adverse long-term outcomes in hypertrophic cardiomyopathy","volume":"5","author":"Fumagalli","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026081102581837600_qcag051-B4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/jce.15304","article-title":"Impact of comorbidities on atrial fibrillation and sudden cardiac death in hypertrophic cardiomyopathy","volume":"33","author":"Sridharan","year":"2022","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026081102581837600_qcag051-B5","doi-asserted-by":"publisher","first-page":"e27445","DOI":"10.1097\/MD.0000000000027445","article-title":"Clinical significance of overweight in patients with hypertrophic cardiomyopathy: a retrospective cohort study","volume":"100","author":"Chen","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2026081102581837600_qcag051-B6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.21037\/cdt-19-587","article-title":"Obesity-related ventricular remodelling is exacerbated in dilated and hypertrophic cardiomyopathy","volume":"10","author":"Rayner","year":"2020","journal-title":"Cardiovasc Diagn Ther"},{"key":"2026081102581837600_qcag051-B7","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1111\/dom.15557","article-title":"The effect of glucagon-like peptide-1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: an updated systematic review and meta-analysis","volume":"26","author":"Zhang","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026081102581837600_qcag051-B8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/HJH.0000000000003903","article-title":"Effects of glucagon-like peptide-1 receptor agonists on blood pressure in overweight or obese patients: a meta-analysis of randomized controlled trials","volume":"43","author":"Wong","year":"2025","journal-title":"J Hypertens"},{"key":"2026081102581837600_qcag051-B9","doi-asserted-by":"publisher","first-page":"133082","DOI":"10.1016\/j.ijcard.2025.133082","article-title":"Cardiovascular outcomes of glucagon-like peptide-1 agonist in patients with obesity and hypertrophic cardiomyopathy","volume":"426","author":"Fath","year":"2025","journal-title":"Int J Cardiol"},{"key":"2026081102581837600_qcag051-B10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1056\/NEJMoa1600869","article-title":"Bariatric surgery versus intensive medical therapy for diabetes\u20145-year outcomes","volume":"376","author":"Schauer","year":"2017","journal-title":"N Engl J Med"},{"key":"2026081102581837600_qcag051-B11","doi-asserted-by":"publisher","first-page":"e005126","DOI":"10.1161\/JAHA.116.005126","article-title":"Gastric bypass surgery produces a durable reduction in cardiovascular disease risk factors and reduces the long-term risks of congestive heart failure","volume":"6","author":"Benotti","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026081102581837600_qcag051-B12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41366-023-01412-3","article-title":"The effects of bariatric surgery on cardiac function: a systematic review and meta-analysis","volume":"48","author":"Sargsyan","year":"2024","journal-title":"Int J Obes (Lond)"},{"key":"2026081102581837600_qcag051-B13","doi-asserted-by":"publisher","first-page":"200179","DOI":"10.1016\/j.ijcrp.2023.200179","article-title":"Weight loss in hypertrophic cardiomyopathy: a clinical case series","volume":"17","author":"Reuter","year":"2023","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"2026081102581837600_qcag051-B14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jacc.2013.03.062","article-title":"Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy","volume":"62","author":"Olivotto","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026081102581837600_qcag051-B15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.hfc.2021.01.003","article-title":"Combined effect of Mediterranean diet and aerobic exercise on weight loss and clinical Status in obese symptomatic patients with hypertrophic cardiomyopathy","volume":"17","author":"Limongelli","year":"2021","journal-title":"Heart Fail Clin"},{"key":"2026081102581837600_qcag051-B16","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1002\/ehf2.14414","article-title":"Effects of bariatric surgery on cardiovascular-related acute care use in patients with hypertrophic cardiomyopathy","volume":"10","author":"Miyashita","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026081102581837600_qcag051-B17","doi-asserted-by":"publisher","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2026081102581837600_qcag051-B18","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int J Biol Sci"},{"key":"2026081102581837600_qcag051-B19","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s13098-025-01917-z","article-title":"Heart failure with preserved ejection fraction and obesity: emerging metabolic therapeutic strategies","volume":"17","author":"Zheng","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"2026081102581837600_qcag051-B20","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s10741-023-10307-4","article-title":"Inflammation across the spectrum of hypertrophic cardiac phenotypes","volume":"28","author":"Lillo","year":"2023","journal-title":"Heart Fail Rev"},{"key":"2026081102581837600_qcag051-B21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s12265-018-9795-z","article-title":"GLP-1 Improves diastolic function and survival in heart failure with preserved ejection fraction","volume":"11","author":"Nguyen","year":"2018","journal-title":"J Cardiovasc Transl Res"},{"key":"2026081102581837600_qcag051-B22","first-page":"586","article-title":"[Effects of GLP-1 agonist exenatide on cardiac diastolic function and vascular endothelial function in diabetic patients]","volume":"46","author":"Wang","year":"2015","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"2026081102581837600_qcag051-B23","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s10557-023-07482-9","article-title":"Liraglutide protects against diastolic dysfunction and improves ventricular protein translation","volume":"38","author":"Rutledge","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026081102581837600_qcag051-B24","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2337\/db12-1025","article-title":"Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP\/PKA\/Rho-dependent mechanism","volume":"62","author":"Wang","year":"2013","journal-title":"Diabetes"},{"key":"2026081102581837600_qcag051-B25","doi-asserted-by":"publisher","first-page":"E664","DOI":"10.1210\/jc.2012-3855","article-title":"Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men","volume":"98","author":"Skov","year":"2013","journal-title":"J Clin Endocrinol Metab"}],"container-title":["European Heart Journal - Quality of Care and Clinical Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjqcco\/advance-article-pdf\/doi\/10.1093\/ehjqcco\/qcag051\/67555025\/qcag051.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/12\/5\/731\/67555025\/qcag051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/12\/5\/731\/67555025\/qcag051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T06:58:26Z","timestamp":1786431506000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article\/12\/5\/731\/8542027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3,30]]},"published-print":{"date-parts":[[2026,8,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjqcco\/qcag051","relation":{},"ISSN":["2058-5225","2058-1742"],"issn-type":[{"value":"2058-5225","type":"print"},{"value":"2058-1742","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,3,30]]}}}